Literature DB >> 24461684

Cannabis use, gender and age of onset of schizophrenia: data from the ÆSOP study.

Kim Donoghue1, Gillian A Doody2, Robin M Murray3, Peter B Jones4, Craig Morgan5, Paola Dazzan3, Jozella Hart5, Rodolfo Mazzoncini6, James H Maccabe3.   

Abstract

An earlier age of onset of schizophrenia has been identified as a poor prognostic indicator. The current study examines the interaction effect of gender and cannabis use on age of onset of schizophrenia and schizoaffective disorder. This research forms part of a two-centre epidemiological study of first-episode psychosis and included individuals with a diagnosis of schizophrenia or schizoaffective disorder and an age of onset between age 16 and 45. Kaplan-Meier curves and Cox proportional hazards regression were used to compare the effects of cannabis use and gender on age of first symptom of schizophrenia. Akaike's information criteria were used to find the model with the best fit to the data. Cannabis users had an earlier age of first symptom than non-users. There was an interaction with gender; the gender difference in age of onset was diminished in cannabis smokers compared with non-cannabis smokers. The model including cannabis use interacting with gender was the most parsimonious model, followed by cannabis use alone. The addition of other illegal drug use did not improve the model. Cannabis use is associated with an earlier age of onset of schizophrenia, and the gender difference in age of onset is reduced among cannabis smokers.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  First-episode; Onset; Positive symptoms; Psychosis; Substance misuse

Mesh:

Substances:

Year:  2014        PMID: 24461684     DOI: 10.1016/j.psychres.2013.12.038

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  25 in total

1.  Persistent cannabis use among young adults with early psychosis receiving coordinated specialty care in the United States.

Authors:  Leslie Marino; Jennifer Scodes; Talia Richkin; Jean-Marie Alves-Bradford; Ilana Nossel; Melanie Wall; Lisa Dixon
Journal:  Schizophr Res       Date:  2020-05-28       Impact factor: 4.939

Review 2.  Marijuana Legalization: Impact on Physicians and Public Health.

Authors:  Samuel T Wilkinson; Stephanie Yarnell; Rajiv Radhakrishnan; Samuel A Ball; Deepak Cyril D'Souza
Journal:  Annu Rev Med       Date:  2015-10-19       Impact factor: 13.739

Review 3.  Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors.

Authors:  Asma Khan; Susan B Powell
Journal:  Schizophr Res       Date:  2017-10-22       Impact factor: 4.939

Review 4.  Cannabis and Psychosis: a Critical Overview of the Relationship.

Authors:  Charles Ksir; Carl L Hart
Journal:  Curr Psychiatry Rep       Date:  2016-02       Impact factor: 5.285

Review 5.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.

Authors:  F Markus Leweke; Juliane K Mueller; Bettina Lange; Stefan Fritze; Cristina E Topor; Dagmar Koethe; Cathrin Rohleder
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

Review 6.  The link between schizophrenia and substance use disorder: A unifying hypothesis.

Authors:  Jibran Y Khokhar; Lucas L Dwiel; Angela M Henricks; Wilder T Doucette; Alan I Green
Journal:  Schizophr Res       Date:  2017-04-14       Impact factor: 4.939

7.  Comorbid substance use disorders in schizophrenia: a latent class approach.

Authors:  Berit Kerner
Journal:  Psychiatry Res       Date:  2014-12-15       Impact factor: 3.222

Review 8.  Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth.

Authors:  Sabina Abidi; Irfan Mian; Iliana Garcia-Ortega; Tania Lecomte; Thomas Raedler; Kevin Jackson; Kim Jackson; Tamara Pringsheim; Donald Addington
Journal:  Can J Psychiatry       Date:  2017-08-02       Impact factor: 4.356

Review 9.  A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.

Authors:  Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2016-04-09       Impact factor: 8.989

10.  Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use.

Authors:  Laura Ferraro; Caterina La Cascia; Diego Quattrone; Lucia Sideli; Domenica Matranga; Veronica Capuccio; Giada Tripoli; Charlotte Gayer-Anderson; Craig Morgan; Musa B Sami; Pak Sham; Lieuwe de Haan; Eva Velthorst; Hannah E Jongsma; James B Kirkbride; Bart P F Rutten; Alexander L Richards; Laura Roldan; Celso Arango; Miquel Bernardo; Julio Bobes; Julio Sanjuan; Jose Luis Santos; Manuel Arrojo; Ilaria Tarricone; Andrea Tortelli; Andrei Szöke; Cristina Marta Del-Ben; Jean-Paul Selten; Michael Lynskey; Peter B Jones; Jim Van Os; Daniele La Barbera; Robin M Murray; Marta Di Forti
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.